Quick Answer
ELITE PHARMACEUTICALS INC /NV/ reported Stockholders Equity of $53.52 million for fiscal year 2025.
ELITE PHARMACEUTICALS INC /NV/ Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $53.52M | -7.1% |
| 2024 | $57.58M | +98.8% |
| 2023 | $28.96M | +14.8% |
| 2022 | $25.22M | +56.2% |
| 2021 | $16.15M | +51.6% |
| 2020 | $10.66M | +524.9% |
| 2019 | -$2.51M | -154.9% |
| 2018 | $4.57M | -82.2% |
| 2017 | $25.66M | +177.5% |
| 2016 | -$33.12M | +4.6% |
| 2015 | -$34.73M | +57.2% |
| 2014 | -$81.20M | -836.2% |
| 2013 | -$8.67M | +42.1% |
| 2012 | -$14.98M | +16.2% |
| 2011 | -$17.87M | -68.6% |
| 2010 | -$10.60M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| December 31, 2025 | $80.31M | +120.4% | +30.4% |
| September 30, 2025 | $61.58M | +30.3% | +29.2% |
| June 30, 2025 | $47.68M | -18.1% | -10.9% |
| March 31, 2025 | $53.52M | -7.1% | +46.8% |
| December 31, 2024 | $36.45M | -21.5% | -22.9% |
| September 30, 2024 | $47.27M | +4.8% | -18.9% |
| June 30, 2024 | $58.25M | +93.4% | +1.2% |
| March 31, 2024 | $57.58M | +98.8% | +24.1% |
- ELITE PHARMACEUTICALS INC /NV/ showed a decrease of -7.1% in Stockholders Equity compared to the prior fiscal year.
- Over the 2010–2025 period, ELITE PHARMACEUTICALS INC /NV/’s stockholders equity has grown by 605.0% (from -$10.60 million to $53.52 million).
- The most recent figure is from ELITE PHARMACEUTICALS INC /NV/’s fiscal year 2024 report (Form 10-K), filed with the SEC on June 30, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: